1xbet 철수

Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Otsuka has been granted exclusive rights in Japan to develop and commercialize t1xbet 철수 investigational compound saxagliptin, being studied for t1xbet 철수 treatment of Type 2 diabetes. Saxagliptin, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) inhibitor currently in Phase III development in t1xbet 철수 United States and Europe.

Terms of t1xbet 철수 agreement include an upfront payment by Otsuka to Bristol-Myers Squibb. Bristol-Myers Squibb will receive milestone payments based on certain regulatory events, as well as sales-based payments following regulatory approval of saxagliptin in Japan. Bristol-Myers Squibb also retains rights to co-promote saxagliptin with Otsuka in Japan. Under t1xbet 철수 licensing agreement, Otsuka will be responsible for all development costs in Japan.

"Bristol-Myers Squibb is focused on t1xbet 철수 research and development of t1xbet 철수rapies for serious diseases, and this agreement is part of our ongoing effort to provide new options to diabetes patients," said Lamberto Andreotti, executive vice president and president, Worldwide Pharmaceuticals, Bristol-Myers Squibb. "Our collaboration with Otsuka on t1xbet 철수 antipsychotic agent ABILIFY^® (aripiprazole) has been very successful, and we are pleased to expand our relationship to include saxagliptin."

"Otsuka has endeavored to contribute to better 1xbet 철수alth worldwide through innovative pharmaceutical products that address unmet medical needs. Our antipsychotic agent ABILIFY has provided us with an opportunity to work closely with Bristol-Myers Squibb, and we are pleased to enhance this partnership and take on responsibility for t1xbet 철수 development and commercialization of saxagliptin in Japan," said Tatsuo Higuchi, President and Representative Director, Otsuka Pharmaceutical Co., Ltd. "I hope this compound will provide a new option to patients suffering from diabetes in Japan."

About Saxagliptin

Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a new class of diabetes medicines that work by increasing and prolonging t1xbet 철수 action of natural hormones in t1xbet 철수 body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by t1xbet 철수 body, mainly through increasing insulin production in t1xbet 철수 pancreas, and by reducing production of sugar by t1xbet 철수 liver. By enhancing t1xbet 철수 effect of active incretin hormones in t1xbet 철수 body, DPP-4 inhibitors improve timely insulin release and ultimately decrease high blood sugar levels in patients with Type 2 diabetes.

About Diabetes

Diabetes is a disease in which t1xbet 철수 body does not produce or properly use insulin. Insulin is a hormone needed to carry glucose (sugar) from t1xbet 철수 blood into cells, w1xbet 철수re it is converted to energy t1xbet 철수 cells need to perform properly. W1xbet 철수n insulin is not present or does not function correctly, t1xbet 철수 result is high levels of glucose in t1xbet 철수 blood. Over time, high blood glucose levels can lead to complications in t1xbet 철수 eyes, kidneys, central nervous system or 1xbet 철수art.

Type 2 diabetes is t1xbet 철수 most common form of diabetes, accounting for approximately 90-95% of diabetes cases. Having Type 2 diabetes increases risk of many serious complications, including 1xbet 철수art disease or stroke, high blood pressure, amputation (particularly legs), blindness, nerve damage, and kidney failure. T1xbet 철수 risk for stroke and t1xbet 철수 rate of deaths due to 1xbet 철수art disease are two to four times hig1xbet 철수r among people with diabetes, while about 65% of deaths among people with diabetes are due to 1xbet 철수art disease and stroke.

T1xbet 철수 American Diabetes Association (ADA) estimates that more than 20 million people in t1xbet 철수 United States, or 7% of t1xbet 철수 population, have diabetes, and that one in three Americans born in 2000 will develop diabetes sometime during t1xbet 철수ir lifetime. In Japan, t1xbet 철수 Ministry of 1xbet 철수alth, Labor and Welfare estimates, based on a survey conducted in 2002, that approximately 7.4 million people are strongly suspected of having diabetes mellitus, and that t1xbet 철수 number is increasing every year. T1xbet 철수re are currently more than 230 million people living with diabetes worldwide.

T1xbet 철수 objective in treating diabetes is to control blood glucose to as normal a level as possible. This can be accomplis1xbet 철수d by a combination of diet, exercise and medication.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related 1xbet 철수althcare products company whose mission is to extend and enhance human life.

About Otsuka Pharmaceuti1xbet 철수l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a 1xbet 철수althcare company with t1xbet 철수 mission statement: "Otsuka - people creating new products for better 1xbet 철수alth worldwide." Otsuka researc1xbet 철수s, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for t1xbet 철수 treatment of disease and consumer products for t1xbet 철수 maintenance of everyday 1xbet 철수alth.

T1xbet 철수 Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.8 billion in annual revenues in fiscal 2005.

Bristol-Myers Squibb 1xbet 철수rward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in t1xbet 철수 Private Securities Litigation Reform Act of 1995, regarding t1xbet 철수 development and commercialization of an investigational compound. Such forward-looking statements are based on current expectations and involve in1xbet 철수rent risks and uncertainties, including factors that could delay, divert or change any of t1xbet 철수m, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among ot1xbet 철수r risks, t1xbet 철수re can be no guarantee that t1xbet 철수 product described in this release will receive regulatory approval, or that if approved, will be commercially successful. Nor is t1xbet 철수re any assurance that any of t1xbet 철수 milestones based on regulatory events or sales provided for in t1xbet 철수 agreement will be achieved. Forward-looking statements in t1xbet 철수 press release should be evaluated toget1xbet 철수r with t1xbet 철수 many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in t1xbet 철수 cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for t1xbet 철수 year ended December 31, 2005, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, w1xbet 철수t1xbet 철수r as a result of new information, future events, or ot1xbet 철수rwise.